[{"address1": "One Amgen Center Drive", "city": "Thousand Oaks", "state": "CA", "zip": "91320-1799", "country": "United States", "phone": "805 447 1000", "fax": "805 447 1010", "website": "https://www.amgen.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh\u00e7et's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.", "fullTimeEmployees": 28000, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert A. Bradway", "age": 61, "title": "Chairman, CEO & President", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 6428574, "exercisedValue": 0, "unexercisedValue": 50993104}, {"maxAge": 1, "name": "Mr. Peter H. Griffith", "age": 65, "title": "Executive VP & CFO", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 3007214, "exercisedValue": 0, "unexercisedValue": 1401880}, {"maxAge": 1, "name": "Dr. David M. Reese M.D.", "age": 61, "title": "Executive VP & CTO", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 3327225, "exercisedValue": 0, "unexercisedValue": 7193319}, {"maxAge": 1, "name": "Mr. Murdo  Gordon", "age": 57, "title": "Executive Vice President of Global Commercial Operations", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 3174030, "exercisedValue": 0, "unexercisedValue": 4835902}, {"maxAge": 1, "name": "Dr. James E. Bradner M.D.", "age": 52, "title": "Executive Vice President of Research & Development", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 4095677, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Esteban  Santos", "age": 56, "title": "Executive Vice President of Operations", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 3006074, "exercisedValue": 0, "unexercisedValue": 12988893}, {"maxAge": 1, "name": "Mr. Matthew C. Busch", "age": 49, "title": "Chief Accounting Officer & VP of Finance", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Scott  Skellenger", "title": "Senior VP & Chief Information Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Howard Y. Chang M.D., Ph.D.", "title": "Senior VP of Global Research & Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Justin G. Claeys", "title": "Vice President of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 2, "shareHolderRightsRisk": 2, "overallRisk": 3, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-IRHome", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 279.84, "open": 279.47, "dayLow": 276.45, "dayHigh": 282.19, "regularMarketPreviousClose": 279.84, "regularMarketOpen": 279.47, "regularMarketDayLow": 276.45, "regularMarketDayHigh": 282.19, "dividendRate": 9.52, "dividendYield": 3.39, "exDividendDate": 1747353600, "payoutRatio": 1.1905, "fiveYearAvgDividendYield": 2.99, "beta": 0.581, "trailingPE": 37.19735, "forwardPE": 13.586841, "volume": 1914460, "regularMarketVolume": 1914460, "averageVolume": 3201963, "averageVolume10days": 2640070, "averageDailyVolume10Day": 2640070, "bid": 280.45, "ask": 281.15, "bidSize": 1, "askSize": 1, "marketCap": 150868656128, "fiftyTwoWeekLow": 253.3, "fiftyTwoWeekHigh": 346.85, "priceToSalesTrailing12Months": 4.5137825, "fiftyDayAverage": 302.1608, "twoHundredDayAverage": 304.78384, "trailingAnnualDividendRate": 9.0, "trailingAnnualDividendYield": 0.032161236, "currency": "USD", "tradeable": false, "enterpriseValue": 199774633984, "profitMargins": 0.122370005, "floatShares": 535840442, "sharesOutstanding": 537204992, "sharesShort": 14543828, "sharesShortPriorMonth": 15062987, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.0271, "heldPercentInsiders": 0.00217, "heldPercentInstitutions": 0.81966, "shortRatio": 4.28, "shortPercentOfFloat": 0.0271, "impliedSharesOutstanding": 537651008, "bookValue": 10.946, "priceToBook": 25.65686, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "earningsQuarterlyGrowth": -0.183, "netIncomeToCommon": 4089999872, "trailingEps": 7.55, "forwardEps": 20.67, "lastSplitFactor": "2:1", "lastSplitDate": 943228800, "enterpriseToRevenue": 5.977, "enterpriseToEbitda": 13.18, "52WeekChange": 0.016137242, "SandP52WeekChange": 0.07995045, "lastDividendValue": 2.38, "lastDividendDate": 1739491200, "quoteType": "EQUITY", "currentPrice": 280.84, "targetHighPrice": 400.0, "targetLowPrice": 185.0, "targetMeanPrice": 314.61807, "targetMedianPrice": 321.5, "recommendationMean": 2.4375, "recommendationKey": "buy", "numberOfAnalystOpinions": 26, "totalCash": 11973000192, "totalCashPerShare": 22.288, "ebitda": 15157000192, "totalDebt": 60878999552, "quickRatio": 0.843, "currentRatio": 1.257, "totalRevenue": 33423998976, "debtToEquity": 1035.886, "revenuePerShare": 62.242, "returnOnAssets": 0.064, "returnOnEquity": 0.67553, "grossProfits": 22965999616, "freeCashflow": 13725875200, "operatingCashflow": 11489999872, "earningsGrowth": -0.187, "revenueGrowth": 0.109, "grossMargins": 0.68711, "ebitdaMargins": 0.45348, "operatingMargins": 0.51805, "financialCurrency": "USD", "symbol": "AMGN", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Amgen Inc.", "longName": "Amgen Inc.", "marketState": "CLOSED", "regularMarketChangePercent": 0.35734704, "regularMarketPrice": 280.84, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 424704600000, "postMarketChangePercent": -0.0854544, "postMarketPrice": 280.6, "postMarketChange": -0.23999, "regularMarketChange": 1.0, "regularMarketDayRange": "276.45 - 282.19", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 3201963, "fiftyTwoWeekLowChange": 27.539993, "fiftyTwoWeekLowChangePercent": 0.1087248, "fiftyTwoWeekRange": "253.3 - 346.85", "fiftyTwoWeekHighChange": -66.01001, "fiftyTwoWeekHighChangePercent": -0.19031285, "fiftyTwoWeekChangePercent": 1.6137242, "dividendDate": 1749168000, "earningsTimestamp": 1746129600, "earningsTimestampStart": 1746129600, "earningsTimestampEnd": 1746129600, "earningsCallTimestampStart": 1746131400, "earningsCallTimestampEnd": 1746131400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 7.55, "epsForward": 20.67, "epsCurrentYear": 20.61491, "priceEpsCurrentYear": 13.623149, "fiftyDayAverageChange": -21.3208, "fiftyDayAverageChangePercent": -0.07056111, "twoHundredDayAverageChange": -23.943848, "twoHundredDayAverageChangePercent": -0.07856009, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.4 - Buy", "cryptoTradeable": false, "corporateActions": [{"header": "Dividend", "message": "AMGN announced a cash dividend of 2.38 with an ex-date of May. 16, 2025", "meta": {"eventType": "DIVIDEND", "dateEpochMs": 1747368000000, "amount": "2.38"}}], "postMarketTime": 1745624408, "regularMarketTime": 1745611202, "exchange": "NMS", "messageBoardId": "finmb_24816", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Amgen", "trailingPegRatio": 0.9439, "__fetch_time": "2025-04-26"}]